Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy

Zhangqiang Xianga,b, Xiangyu Denga, Wenfeng Hea, Qian Yanga, Laichao Ni, Marzieh Dehghan Shasaltanehd, Mazaher Maghsoudlooe,f, Gang Yanga, Jingbo Wa,c, Saber Imaniamma and Qinglian Wen a

aDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China; bPhase 1 Clinical Trial Center, Deyang People’s Hospital, Deyang, China; cNuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China. The Affiliated Hospital of Southwest Medical University, Luzhou, China; dDepartment of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran; eLaboratory of Systems Biology and Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; fDepartment of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; gDepartment of Oncology, Anyue Hospital of Traditional Chinese Medicine, Second Ziyang Hospital of Traditional Chinese Medicine, Ziyang, China

ABSTRACT
Background: Vascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers that inhibit lung cancer cell proliferation and the development of pleural effusion.

Methods: In this study, we established Lewis lung cancer (LLC) xenograft mouse models to compare the therapeutic effect of APA and BEV in combination with cisplatin (CDDP) against MPE. The anti-tumour and anti-angiogenic effects of this combination therapy were evaluated by 18F-FDG PET/CT imaging, TUNEL assay and Immunohistochemistry.

Results: The triple drug combination significantly prolonged the overall survival of the tumour-bearing mice by reducing MPE and glucose metabolism and was more effective in lowering VEGF/soluble VEGFR-2 levels in the serum and pleural exudates compared to either of the monotherapies. Furthermore, CDDP + APA + BEV promoted in vivo apoptosis and decreased microvessel density.

Conclusions: Mechanistically, LLC-induced MPE was inhibited by targeting the VEGF-MEK/ERK pathways. Further studies are needed to establish the synergistic therapeutic effect of these drugs in NSCLC patients with MPE.

KEY MESSAGES
Combined treatment of MPE with apatinib, bevacizumab and cisplatin can prolong the survival time of mice, reduce the content of MPE, decrease the SUVmax of thoracic tumour tissue, down-regulate the content of VEGF and sVEGFR-2 in serum and pleural fluid, and promote the apoptosis of tumour cells. Angiogenesis and MPE formation can be inhibited by down-regulation of HIF-1α, VEGF, VEGFR-2, MEK1 and MMP-2 molecular signalling pathway proteins.

Abbreviations: APA: Apatinib; BEV: Bevacizumab; CD31: Cluster of differentiation 31; CDDP: Cisplatin; ERK: Extracellular signal-regulated kinase; ELISA: Enzyme-linked immunosorbent assay; 18F-FDG: 18F-fluorodeoxyglucose; HIF-1α: Hypoxia-inducible factor-1α; IPC: Indwelling pleural catheter; LLC: Lewis lung cancer; MPE: Malignant pleural effusion; MEK: Mitogen-activated protein kinase; MEK1: MAPK/ERK kinase 1; MMP-2: Matrix metalloproteinase 2; MVD: Microvessel density; OS: Overall survival; NSCLC: Non-small cell lung cancer; PlGF: Placenta growth factor; PET/CT: Positron emission computed tomography; ROI: Region of interest; SPFF: Specific pathogen free; sVEGFR-2: Soluble vascular endothelial growth factor receptor 2; SUVmax: Maximum standard uptake value; TKI: Tyrosine kinase inhibitor; VEGF: Vascular endothelial growth factor

CONTACT Qinglian Wen wql73115@hotmail.com Department of Oncology, The Affiliated Hospital of Southwest Medical University, #25 Taiping Street, Jiangyang District, Luzhou City, 646000, Sichuan Province, P.R. China; Saber Imani saberimani@swmu.edu.cn Co-first author with equal contribution.

**Present address: China Regional Research Center, International Centre for Genetic Engineering and Biotechnology, Taizhou, Jiangsu 225300, China.

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Non-small-cell lung cancer (NSCLC) is the most prevalent among all lung malignancies, and accounts for most cancer-related deaths with an annual mortality rate of 1.6 million worldwide [1,2]. The first-line treatment against NSCLC includes surgery, chemo-immunotherapy or radiotherapy. Furthermore, several molecular therapies targeting immune checkpoints, epidermal growth factor receptor (EGFR), tyrosine kinases and cell cycle mediators have been developed in recent years. Nevertheless, the overall 5-year survival rate of NSCLC patients remains less than 14% [3]. The Lewis lung cancer (LLC) cell line was established from the lung tissues of C57BL/6 mice implanted with primary Lewis lung carcinoma cells. LLC is highly metastatic in immunocompetent mice and is routinely used to evaluate the efficacy of chemotherapeutic agents in vivo [4].

Malignant pleural effusion (MPE) is a common complication of advanced NSCLC that significantly lowers patient quality of life and shortens the overall survival (OS) [5]. It can be cleared by thoracentesis, intra-pleural drug infusion, biological response modifiers and drainage via simple puncture, although the final outcomes are usually unsatisfactory. The molecular mechanisms underlying the induction of MPE are complex and poorly understood. However, recent studies have implicated angiogenesis to be an important factor [6,7]. The metastatic pleural tumour cells infiltrate into lymphatic vessels and block reflux absorption of the pleural fluid, which triggers local inflammation in the pleura. The ensuing increase in the levels of vasoactive mediators such as vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF) and chemokine ligand (CCL) 2, and the decrease in protective factors like endostatin increase the permeability of the pleural capillary walls, eventually leading to MPE [8]. Furthermore, the upregulation of oncogenic transcription factors in the pleural exudates exacerbates inflammation, vascular leakage, angiogenesis, tumour dissemination, and drug resistance. The VEGF family promotes endothelial cell proliferation and angiogenesis and is also associated with MPE in patients with advanced NSCLC [9,10]. Pre-clinical and clinical studies show that decreasing VEGF levels in NSCLC patients can significantly control pleural effusion [6,11,12]. Therefore, VEGF-targeted therapies are a viable palliative strategy for patients with MPE.

Bevacizumab (tradename: Avastin; BEV), a recombinant humanized monoclonal antibody targeting VEGF, was the first anti-angiogenic drug approved in the United States to treat MPE [13,14]. It binds to human VEGF (VEGF-A) and blocks the VEGF-VEGFR pathway, thereby inhibiting the growth of new blood vessels in the tumour and promoting tumour cell apoptosis. The tyrosine kinase inhibitor (TKI) apatinib (YN968D1, APA) selectively targets VEGFR-2 [15,16] and has been approved for treating advanced or metastatic chemo refractory gastric cancer in China [17,18]. APA can effectively block the kinase activity of VEGFR-2, c-kit and c-src, as well as the phosphorylation of VEGFR-2, c-kit and platelet-derived growth factor receptor beta (PDGFRb) [19]. It can inhibit the proliferation, migration and tubular formation of human umbilical vein endothelial cells in vitro, and the germination of aortic rings in rats [12,19–21]. In addition, APA has shown satisfactory efficacy against solid tumours with tolerable side effects [21–23]. Interestingly, the combination of APA with other chemotherapeutic drugs can effectively inhibit the growth of various human xenografts in animal models [19,24,25]. However, the effect of APA either alone or in combination with other anti-angiogenic drugs on MPE has not been reported so far.

VEGFR-1 and VEGFR-2 are the main receptors of VEGF that relay signals of cell proliferation, angiogenesis, and vascular permeability [26,27]. VEGFR-2-dependent endothelial cell proliferation in NSCLC tumours is directly correlated with MPE [28,29] and can be controlled by intrathoracic administration of cisplatin (CDDP). Several studies have reported beneficial outcomes of the combination of traditional chemotherapeutic drugs and anti-angiogenic drugs against solid tumours [30–34]. We recently reported the efficacy of the simultaneous angiogenesis blockade in NSCLC with BEV and APA [8], and the combination of BEV and CDDP is an effective and safe option for clearing MPE [35,36]. Several studies have shown that intrapleural anti-VEGF and/or anti-EGFR administration reduced pleural fluid volume and the levels of inflammatory mediators without affecting patient survival [37]. Furthermore, VEGFR-2 blockade alone is not sufficient to achieve the maximum therapeutic effect against MPE since tumour-derived VEGF can also promote metastasis via the VEGF/VEGFR-1 signalling pathway [38]. However, the therapeutic efficacy of anti-angiogenic drugs in combination with CDDP, and the underlying mechanisms, remain unclear [39,40]. To this end, we evaluated the effects of the triple combination of BEV, APA and CDDP on Lewis lung cancer (LLC) cell-induced MPE in a mouse model. The novel drug combination inhibited tumour angiogenesis and growth by targeting the VEGF/VEGFR-related pathways and can potentially improve the prognosis of NSCLC patients with MPE.
Materials and methods

Drugs and reagents

APA mesylate tablets (Aitan) were purchased from Hengrui Co. Ltd. (Lianyungang, Jiangsu, China), BEV from Roche Pharmaceutical Co. Ltd. (Shanghai, China), and CDDP from Jiangsu Hansoh Pharma Group Co. Ltd. (Lianyungang, Jiangsu, China). The optimum doses and timing for APA [19,41], BEV and CDDP [13,42] were determined based on previous reports and a preliminary experiment was as follows: CDDP – 2 mg/kg per day once a week, APA – 200 mg/kg per day daily, and BEV – 5 mg/kg twice a week.

Cell culture

LLC cell line was purchased from Otwo Biotech (catalog number: HTX1771; Shenzhen Inc., Guangdong, China) and cultured in Dulbecco’s Modified Eagle’s medium (DMEM, HyClone, Thermo Scientific, USA) supplemented with 10% foetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) and 1% (v/v) antibiotics (100 units/mL penicillin G sodium and 100 μg/mL streptomycin sulphate; Sigma-Aldrich, St Louis, MO, USA) under 5% CO₂ at 37°C. The cell line was fingerprinted within 6 months of the experiments [43].

Establishment of LLC xenograft model of MPE and treatment regimen

In this study, we were established a MPE mouse model with LLC cell lines according to the standard model [43–45]. For more details, 98 male C57BL/6 mice (age 6–8 weeks) were purchased from Dashuo Animal Laboratory Centre (Chengdu, China) and housed in specific-pathogen-free (SPF) conditions at 21 ± 1°C, 40 ± 10% relative humidity and a 12-h light/dark cycle, with ad libitum access to water and food. The MPE xenograft model was established by injecting 200 μL LLC cell suspension (1 × 10^6 cells/mL) into the right thoracic cavity of each mouse anaesthetised with 1% pentobarbital (50 mg/kg) through the right axillary and the sixth costal space [43]. Nine days later, the mice were intrathoracically injected with different combinations of BEV and CDDP [45] and given oral gavage of APA or intra-lumen injection of normal saline for eight consecutive days (n = 14 each, n = n1 + n2) [46]. The specific treatment groups were as follows: (1) Control – intra-lumen injection of 0.1 mL normal saline on day 10 and tube feeding with 0.5 mL from days 11 to 17, (2) CDDP – 2 mg/kg CDDP on day 10, (3) APA – normal saline on day 10 and 200 mg/kg APA from days 11 to 17, (4) BEV – normal saline on day 10 and 5 mg/kg BEV on days 11 and 15, (5) CDDP + APA group: 2 mg/kg CDDP on day 10 and 200 mg/kg APA from days 11 to 17, (6) CDDP + BEV group: 2 mg/kg CDDP on day 10 and 5 mg/kg BEV on days 11 and 17, and (7) CDDP + APA + BEV group: 2 mg/kg CDDP on day 10, 200 mg/kg APA from days 11 to 17, and 5 mg/kg BEV on days 11 and 15. Six mice were randomly selected from each group (n1) for overall survival analysis, and the remaining 8 (n2) were monitored twice a day for changes in body weight and euthanized on the day 19. The general conditions of the animals, including eating, activity, appearance, and response to external stimuli, were observed twice a day. We carried out euthanasia through excessive anaesthesia. The specific method was to closely observe the condition of the mice after intraperitoneal injection of pentobarbital (150 mg/kg). When the voluntary breathing disappeared, the voluntary heartbeat was suspended, and the eyeball pupil was fixed and dilated, the mice were determined to be dead. On day 19, mice (n2) were euthanized under anaesthesia. After euthanasia, all samples, blood, pleural exudates and tumour tissues, were collected, and the volume of bilateral pleural effusion was measured. The tumour-bearing mice were dissected and the gross findings were photoed. Three days after the detection of tumour growth, all the remaining mice underwent PET/CT to observe the MPE formation and calculate the rate of MPE formation at this time point. The observation was repeated on the 18th day, and the rates of MPE formation were also calculated. As previously described [8], the pleural effusion in the bilateral thoracic cavity was gently extracted using a syringe and the fluid volume was recorded. All procedures were conducted as per the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978), and approved by the Institutional Animal Care and Treatment Committee of Southwest Medical University, Luzhou, Sichuan, China.

18f-FDG micro-positron emission tomography (PET)/computed tomography (CT) imaging

The metabolic status of the tumour tissues was analysed on day 18 in the n2 group by 18F-FDG micro-PET/CT using the Inveon micro PET/CT animal scanner (Siemens, Munich, Germany). Briefly, the mice were fasted for at least 8 h before the scan and anaesthetized by an intraperitoneal injection of 1% pentobarbital at the dose of 50 mg/kg [47]. Fifteen minutes later, the animals were checked for depth of anaesthesia by a toe pinch to verify no response and then...
were injected with $^{18}$F-FDG. Each mouse was then injected with 0.1–0.2 mL of 150–200 $\mu$Ci $^{18}$F-FDG through the tail vein and placed in the centre of the PET/CT ring field of view 30–40 min later. After induction of anaesthesia, mice were placed in a supine position, with their heads fixed [47]. Whole body scans were performed in the 2D mode with 10 min per bed position. Other scanning parameters were 80 kV, 500 $\mu$A and 1.5 mm slice collimation. The tumour region of interest (ROI) in the chest cavity of each mouse was delineated, and the maximum standardized uptake (SUV$_{\text{max}}$) was calculated using the single hottest pixel within the tumour. The PET/CT images and data were analysed by two nuclear medicine experts.

**Immunohistochemistry**

The tumour nodules were fixed in 10% neutral formaldehyde, embedded in paraffin, and cut into 5-μm-thick sections. For immunohistochemical analysis, the tumour sections were dewaxed and soaked in 0.01 M sodium citrate (pH 6) for 24 h, and heated in a pressure cooker heated for 90 s. After blocking non-specific reactions with 2% normal mouse serum (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at room temperature (RT), the sections were incubated in levamisole (Vector Laboratories, Burlingame, CA) to quench endogenous alkaline phosphatase. The slides were then rinsed with PBS, and incubated overnight with rabbit anti-hypoxia-inducible factor (HIF)-1α (1:100, Bioss Biotechnology Co. Ltd., Beijing, China), anti-VEGF (1:200, Abcam Trading Co. Ltd., Shanghai, China), anti-VEGFR-2 (1:200, Abcam Trading Co. Ltd., Shanghai, China), anti-MEK1 (1:300, Abcam Trading Co. Ltd., Shanghai, China), anti-cluster of differentiation 31 (CD31) (1:200, Abcam Trading Co. Ltd., Shanghai, China), and anti-matrix metalloproteinase (MMP)-2 (1:100, Proteintech Group Inc., Wuhan, China) primary antibodies at 4°C. Normal anti-rabbit IgG, normal pre-immune anti-goat IgG, or tris-buffered saline were used as negative controls. After washing once, the sections were sequentially probed with biotinylated goat anti-rabbit IgG and horseradish peroxidase-labelled anti-goat secondary antibody (1:200, Aspen medical products Co. Ltd., California, USA) for 50 min at RT, rinsed four times with PBS, and incubated with DAB substrate (ZLI-9033, ZSGB Biotechnology Co. Ltd., Beijing, China) until the desired colour was achieved (Table 1). Subsequently, the sections were counterstained with haematoxylin, dehydrated through an ethanol gradient and xylene, and fixed with neutral glue. All sections were visualized under the Axiosoplan 2 microscope (Zeiss, Toronto, ON, Canada) and the images were analysed using Zeiss Axiosvision software (Zeiss; New York, NY, USA). Five random, non-overlapping fields per section were observed at 100× and 400× magnification using a MicroPublisher imaging system (Q-IMAGING, Surrey, BC, Canada), and the immuno-positive areas were evaluated by two independent pathologists. All sections were counterstained in haematoxylin nuclear fast red for 10 min. The expression intensities of the different proteins were calculated as $a/b \times 100\% \times c$ [48], where $a$, $b$ and $c$ respectively indicate the positively stained area, total area and average grey level of each section at 400× magnification. The microvessel density (MVD) was calculated as the mean area occupied by microvessels in five CD31$^+$ hotspots at 100× magnification. In addition, the number of microvessels was counted in these areas at 400×, and the average was calculated [49]. The images were separately analysed by two pathologists.

**Enzyme-linked immunosorbent assay (ELISA)**

The levels of soluble VEGFR-2 (sVEGFR-2) and VEGF in the blood and pleural exudates were evaluated using specific sandwich ELISA kits according to the manufacturer’s instructions (Wuhan, Boster Biological Technology, China). The absorbance [optical density (OD) value] of each well at 450 nm was measured within 10 min of adding the stop solution provided in the kit, and the values were normalized to that of the blank. A standard curve was then plotted according to the concentration of the standards and the corresponding OD values, and the amount of sVEGFR-2 and

### Table 1. Detailed profiles of used antibodies.

| Antibody name | Supplier          | Clone        | Catalogue No. | Dilutions | Incubation Time/Temp. |
|---------------|-------------------|--------------|---------------|-----------|-----------------------|
| CD31          | Abcam             | Rabbit polyclonal | ab28364       | 1:200    | Overnight at 4°C      |
| HIF-1α        | Bios              | Rabbit polyclonal | bs-0737R      | 1:100    | Overnight at 4°C      |
| VEGF          | Abcam             | Rabbit polyclonal | ab25297       | 1:200    | Overnight at 4°C      |
| VEGFR-2       | Abcam             | Rabbit polyclonal | ab194806      | 1:200    | Overnight at 4°C      |
| MEK1          | Abcam             | Rabbit polyclonal | ab178876      | 1:300    | Overnight at 4°C      |
| MMP-2         | Proteintech Group | Rabbit polyclonal | 10373-2-AP    | 1:100    | Overnight at 4°C      |

HIF-1: hypoxia-inducible factor-1; HRP: horseradish peroxidase; MEK1: MAPK/ERK kinase 1; MMP-2: matrix metalloproteinase 2; VEGF: vascular endothelial growth factor; VEGFR-2: vascular endothelial growth factor receptor 2.
VEGF was calculated using a regression equation. The lower limit of detection for sVEGFR-2 was 300 ng/L and that for VEGF was 12.5 ng/mL. The ELISA reader and washer used in this study were Stat-Fax 2100 and Stat-Fax 2600 (USA), respectively.

### Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay

Pleural tumour tissues were stained using a TUNEL kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer’s protocol, and imaged and analysed using Image J in a blinded manner. The TUNEL-positive apoptotic cells were counted in at least five random fields (magnification: 200×), and the relative percentage was calculated. The experiment was repeated thrice.

### Statistical analysis

All statistical analyses were performed using SPSS software version 23.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism software version 7.0 (GraphPad Software Inc., La Jolla, CA, USA). All tests were repeated three times or more. Quantitative data are expressed as mean ± standard deviation. Multiple groups were compared by one-way analysis of variance (ANOVA), and the average number of pairwise comparisons was determined by Tukey’s test. Spearman’s rank correlation coefficient test was used to determine the association between two variables. Survival duration and rate were evaluated by the Kaplan-Meier method, and the log-rank test was used to compare survival curves. For all tests, two-sided *p* values less than .05 were considered statistically significant.

### Results

**CDDP + APA + BEV prolonged survival and decreased LLC growth and pleural effusion**

The effects of BEV, CDDP, APA and their different combinations were tested in an LLC-induced MPE model. The grouping, therapeutic regimens and subsequent analyses are outlined in Figure 1.

As shown in Figure 2(A), on day 19, the body weight of the mice treated with BEV (20.40 ± 0.26 g), APA (20.21 ± 0.24 g) or CDDP (19.50 ± 0.24 g) alone was significantly higher than that of the mice treated with normal saline (Control: 18.00 ± 0.24 g; *p* < .01). Combining CDDP with either APA (21.00 ± 0.16 g) or BEV (20.80 ± 0.28 g) further improved the body weight of tumour-bearing mice (*p* < .01 compared to control), although no significant difference was observed between the CDDP + APA and CDDP + BEV groups (*p* = .67). The highest average body weight was observed in the CDDP + APA + BEV group (21.53 ± 0.28 g). Consistent with this finding, the drug triad also significantly prolonged the median survival of tumour-bearing mice to 30 days compared with only 20 days observed in the control group (Figure 2(B)). Furthermore, APA (25 days), BEV (25 days) and CDDP (22 days) monotherapies also prolonged survival (*p* < .01 compared to Control), although the individual drugs were less effective compared to their combination (*p* < .01). Finally, pleural effusion volume was also significantly lower in the CDDP + APA + BEV group (0.59 ± 0.06 mL) compared with that in the CDDP + BEV group.

![Figure 1](image_url). BEV, APA and CDDP treatment regimen. Each arrow corresponds to the individual drug. APA: apatinib; BEV: bevacizumab; CDDP: cisplatin; PET/CT: Fluorine-18-fluorodeoxyglucose (18F-FDG) micro-posietron emission tomography/computed tomography.
(0.78 ± 0.04 mL), CDDP + APA (0.79 ± 0.04 mL), APA (1.05 ± 0.11 mL), BEV (1.01 ± 0.08 mL) and CDDP (1.32 ± 0.06 mL) groups. CDDP + APA and CDDP + BEV had a similar effect on MPE as that observed with body weight (\( p = 1.00 \)). Taken together, the combination of BEV, APA and CDDP significantly decreased tumour growth and pleural effusion and prolonged the survival of the tumour-bearing mice compared to the individual drugs.

**The triple combination therapy reduced glucose metabolism in LLC xenografts**

The metabolic effects of different therapies were evaluated by \(^{18}\)F-FDG PET/CT (Figure 3) with SUV\(_{\text{max}}\) as the quantitative index for radioactive uptake [50]. The SUV\(_{\text{max}}\) values for BEV (3.58 ± 0.18), CDDP (4.03 ± 0.18) and APA (3.36 ± 0.17) monotherapies were significantly lower than that for the control group (4.49 ± 0.29). The different combinations of APA, BEV and CDDP further lowered the SUV\(_{\text{max}}\) values, with the lowest was observed for CDDP + APA + BEV (2.41 ± 0.33). No significant differences were observed between the CDDP + APA and CDDP + BEV groups (2.71 ± 0.34 vs 2.76 ± 0.39; \( p = 1.00 \)). Taken together, the combination therapy inhibited the growth of tumour nodules in the pleural cavity by effectively reducing glucose metabolism.

**The triple combination therapy inhibited angiogenesis in tumour tissues**

Tumour growth and angiogenesis were also evaluated in terms of the MVD. As shown in Figure 4(A), the combination therapy significantly decreased the intensity of CD31\(^+\) staining in the tumour tissues compared to the monotherapies and untreated control. Consistent with this, the MVD in the pleural tumour nodules was significantly decreased in the CDDP + APA + BEV
(2.80 ± 0.83), CDDP + BEV (7.60 ± 0.87) and CDDP + APA (7.04 ± 1.12) groups compared to that in each of the monotherapy groups and the control group (21.13 ± 1.55). The MVD was highest in the untreated controls, followed by the CDDP, BEV, APA, CDDP + BEV, CDDP + APA and CDDP + APA + BEV groups in that order. Taken together, BEV and APA in combination with CDDP synergistically inhibited tumour angiogenesis, resulting in significant tumour regression.

As shown in Figure 5, the apoptotic index of pleural tumour nodules was markedly higher in the CDDP + APA + BEV group compared with that in other groups. The percentage of TUNEL + apoptotic tumour cells was highest in mice treated with the drug triad, followed by CDDP + APA, CDDP + BEV, BEV, APA and CDDP in that order (Figure 5(A)) and were significantly higher compared that in the untreated controls (p < .01). Furthermore, the apoptosis rate was significantly higher in the CDDP + APA + BEV group compared to the rest (8.85 ± 1.23%, p < .01 vs. all). The combination of APA or BEV with CDDP increased apoptosis compared to either monotherapy (p < .01). Therefore, the combination of an angiogenesis blocker with CDDP can synergistically induce apoptosis in the tumour cells.

The combination of APA or BEV with CDDP synergistically induced apoptosis of tumour cells

As shown in Figure 5, the apoptotic index of pleural tumour nodules was markedly higher in the CDDP + APA + BEV group compared with that in other groups. The percentage of TUNEL + apoptotic tumour cells was highest in mice treated with the drug triad, followed by CDDP + APA, CDDP + BEV, BEV, APA and CDDP in that order (Figure 5(A)) and were significantly higher compared that in the untreated controls (p < .01). Furthermore, the apoptosis rate was significantly higher in the CDDP + APA + BEV group compared to the rest (8.85 ± 1.23%, p < .01 vs. all). The combination of APA or BEV with CDDP increased apoptosis compared to either monotherapy (p < .01). Therefore, the combination of an angiogenesis blocker with CDDP can synergistically induce apoptosis in the tumour cells.

The combination of APA or BEV with CDDP synergistically induced apoptosis of tumour cells

As shown in Figure 5, the apoptotic index of pleural tumour nodules was markedly higher in the CDDP + APA + BEV group compared with that in other groups. The percentage of TUNEL + apoptotic tumour cells was highest in mice treated with the drug triad, followed by CDDP + APA, CDDP + BEV, BEV, APA and CDDP in that order (Figure 5(A)) and were significantly higher compared that in the untreated controls (p < .01). Furthermore, the apoptosis rate was significantly higher in the CDDP + APA + BEV group compared to the rest (8.85 ± 1.23%, p < .01 vs. all). The combination of APA or BEV with CDDP increased apoptosis compared to either monotherapy (p < .01). Therefore, the combination of an angiogenesis blocker with CDDP can synergistically induce apoptosis in the tumour cells.

The drug triad downregulated VEGF/sVEGFR-2 level in tumour-bearing mice

To gain further insights into the mechanisms underlying the anti-angiogenic effects of BEV, APA and CDDP, we next analysed the levels of VEGF and sVEGFR-2 in the serum and pleural fluid of the tumour-bearing mice. As shown in Figure 6(A), VEGF levels in the serum (22.85 ± 2.20 ng/mL; p < .01 vs. all) and pleural exudates (31.96 ± 3.04 ng/mL; p < .05 vs. all) of mice in the CDDP + APA + BEV group were the lowest compared to that in other treatments groups. Consistent with this, the level of sVEGFR-2 was the highest in the untreated control group in the serum and pleural fluid, followed by the CDDP, BEV, APA, CDDP + BEV, CDDP + APA and CDDP + APA + BEV groups in that order. There was a significant difference between other groups with CDDP + APA + BEV (p < .05). Taken together, CDDP + APA + BEV achieved simultaneous inhibition of
VEGF and sVEGFR-2 in the serum and pleural fluid, which decreased neo-angiogenesis and growth.

The triple drug combination therapy synergistically inhibited the VEGF/MAPK/ERK pathway in pleural tumour nodules

The MAPK pathway is a critical oncogenic pathway and the target of multiple chemotherapeutic drugs [51]. Therefore, we next analysed the expression levels of the downstream VEGF-induced mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signalling pathway. As shown in Figures 7 and 8, the triple drug combination therapy synergistically inhibited the in situ levels of HIF-1α, VEGF, VEGFR-2, MEK1 and MMP-2 proteins compared the control group (p < .01), as well as the monotherapy groups (p < .01). Interestingly, HIF-1α, VEGF, VEGFR-2 and MMP-2 expression was similar between the CDDP + APA and CDDP + BEV groups (p > .05). These findings indicate that BEV, APA and CDDP inhibited angiogenesis in LLC xenografts by blocking the MAPK/ERK and Ras/Raf/MEK/ERK pathways.

Discussion

The aim of our study was to analyse the possible synergistic effect of the combination of BEV, APA and
CDDP against NSCLC complicated with MPE. The combination therapy induced apoptosis in LLC cells and reduced the volume of pleural effusion in tumour-bearing mice, which significantly prolonged their survival. Mechanistically, the drug triad suppressed NSCLC growth and angiogenesis by inhibiting the VEGF-induced MAPK/ERK signalling pathway. This is the first study to identify the therapeutic value of combining BEV, APA and CDDP in NSCLC.

VEGF plays a vital role in promoting angiogenesis and the pleural invasion of VEGF-overexpressing tumour cells initiates MPE formation [52]. At present, MPE clearance mainly relies on intra-pleural administration of antineoplastic agents, thoracentesis, pleurodesis, and the use of an indwelling pleural catheter (IPC) [53,54]. Although the exact mechanism of MPE formation is unclear, there is evidence implicating direct invasion of tumour cells into the pleura, tumour-induced blockade of blood and lymphatic capillaries, obstruction of lymphatic circulation by lymph node metastasis, and increased permeability of pleural capillary walls induced by tumour-secreted cytokines. Studies show that VEGF-dependent angiogenesis and increased capillary permeability are the main factors

Figure 5. Combination of bevacizumab, apatinib and cisplatin increased apoptosis in mouse xenografts. (A) Representative images of TUNEL-stained (green) sections counterstained with DAPI (blue). Original magnification, ×200. (B) Percentage of TUNEL-positive cells in the pleural tumour nodules. ** p < .01 vs CDDP + APA + BEV. APA: apatinib; BEV: bevacizumab; CDDP: cisplatin; n.s.: not significant; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labelling.

Figure 6. Combination therapy synergistically down-regulated VEGF/sVEGFR-2. Bar graphs showing VEGF (A) and sVEGFR-2 (B) levels in the serum and pleural exudates of the differentially treated mice. * p < .05, ** p < .01 vs CDDP + APA + BEV; † p < .05, ‡ p < .01 vs CDDP + BEV. APA: apatinib; BEV: bevacizumab; CDDP: cisplatin; n.s.: not significant; sVEGFR-2: soluble vascular endothelial growth factor receptor 2; VEGF, vascular endothelial growth factor.
Figure 7. Representative images showing immunostaining for HIF-1α, VEGF, VEGFR-2, MEK1 and MMP-2 in the tumour tissues of the indicated groups (original magnification, ×400). APA: apatinib; BEV: bevacizumab; CDDP: cisplatin; HIF-1α: hypoxia-inducible factor-1α; MEK1: MAPK/ERK kinase 1; MMP-2: matrix metalloproteinase 2; VEGF: vascular endothelial growth factor; VEGFR-2: vascular endothelial growth factor receptor 2.

Figure 8. Combination therapy targets the VEGF-induced MAPK/ERK signalling pathway in tumour nodules. Horizontal bars show mean ± SD of cells positive for HIF-1α, VEGF, VEGFR-2, MEK1 and MMP-2. ** p < .01 vs CDDP + APA + BEV; # p < .05 vs CDDP + BEV. APA: apatinib; BEV: bevacizumab; CDDP: cisplatin; HIF-1α: hypoxia-inducible factor-1α; MEK1: MAPK/ERK kinase 1; MMP-2: matrix metalloproteinase 2; n.s: not significant; SD: standard deviation; VEGF: vascular endothelial growth factor; VEGFR-2: vascular endothelial growth factor receptor 2.

inducing MPE [55]. VEGF promotes vascular leakage by opening the intercellular junctions and creating a fenestration on the endothelial lining [55], and its levels are significantly higher in malignant as opposed to benign pleural exudates [56]. VEGFR-1 and VEGFR-2 overexpression also aggravate MPE and tumour...
angiogenesis via autophosphorylation and endothelial cell signal transduction [57,58]. Thus, reducing VEGF levels can effectively control pleural effusion. BEV and APA are novel angiogenesis blockers that respectively target VEGF-A and VEGFR-2 [17,59]. Studies increasingly show that an anti-angiogenic drug combination can significantly reduce MPE and recurrent ascites formation by targeting VEGFR-2 [29,60]. Furthermore, intrapleural injection of the platinum-based CDDP is routinely used to kill tumour cells and control MPE since the drug cannot cross the pleural barrier easily and therefore accumulates over time to therapeutically high concentrations. However, the combination of BEV and CDDP can clear MPE with an 80% effectiveness rate compared to 47.8% of CDDP alone [36].

The decrease in MPE relieves the squeezing of lungs and reduces severe hypoxia, which increases food intake in mice [8,61,62]. Previous studies have shown that the drug combination can inhibit the growth of transplanted tumours in mouse models without significant weight loss and toxicity, and prolong survival [63,64]. In our study as well, combining CDDP with either APA or BEV maintained the body weight of tumour-bearing mice, which can be attributed to the higher food intake compared to the untreated control animals. Tumour growth inhibition is accompanied by reduced 18F-FDG uptake, which is indicative of lower glucose metabolism and better prognosis in vivo [65–67]. Studies have correlated a lower SUVmax of tumour masses to slower tumour growth and a better clinical outcome [68,69]. We found that the different drug combinations significantly reduced 18F-FDG uptake by the tumours compared to the monotherapies.

Soluble VEGFR-2 (sVEGFR2) contains the extracellular domain of the VEGFR-2 receptor but lacks the tyrosine kinase domain and is activated in the hypoxic tumour microenvironment [70,71]. W. Xu et al. [72] found that the plasma sVEGFR-2 levels in renal cancer patients decreased significantly following surgical resection and adjuvant treatment with VEGFR-targeting TKIs. Consistent with this, the combination treatment significantly decreased VEGF and sVEGFR-2 levels in the serum and pleural exudates of LLC xenograft-bearing mice, which likely translates to decreased neo-angiogenesis, normalised tumour blood vessels, and a more balanced tumour microenvironment.

The combination of BEV, APA and CDDP inhibited neo-angiogenesis in the LLC xenografts by blocking the MAPK/ERK and Ras/Raf/MEK/ERK pathways, and had a more pronounced effect on HIF-1α and MMP-2 than either drug alone. HIF-1 is the key activator of hypoxia-induced angiogenesis and is regulated by the tumour suppressor gene von Hippel Lindau (VHL). Under normoxic conditions, HIF-1α is rapidly degraded by the ubiquitin-proteasome pathway under the control of VHL. However, hypoxia or VHL deletions/mutations results in the heterodimerization of HIF-1α and HIF-1β, which then translocates to the nucleus and activates VEGF transcription [73]. MMP-2 is an oncogenic protein that degrades extracellular matrix proteins and triggers mediates matrix remodelling and vascularization [74]. It lies downstream of the VEGF signalling cascade and plays an important role in the invasion and metastasis of tumour cells. Studies show that binding of VEGF with VEGFR-2 receptor induces dimerization of the latter, which promotes tumour angiogenesis by activating the C-RAF-MEK-MAPK pathway [75,76]. VEGF/VEGFR-2 interaction also increases microvascular permeability, and the proliferation, invasion, migration and survival of endothelial cells [77,78]. As shown in Figure 9, CDDP, APA and BEV simultaneously target different intermediates in the VEGF-induced MAPK/ERK signalling pathway and NRF2-dependent antioxidant response pathways, which enhances the anti-tumour effect.

The present study has some limitations that ought to be considered. The small sample size and short study duration may have affected the results. In addition, we did not analyse the molecular and cellular mechanisms underlying the synergistic action of BEV, APA and CDDP. Further studies are needed to determine the long-term and short-term toxicity profiles of these drugs, as well as the mechanistic basis of their action. Some in vitro studies have shown that inhibition of VEGF signalling effectively stimulates antitumour immunity and enhances the efficacy of TKIs and immune checkpoint blockade [76,79,80]. For example, the combination of BEV + Atezolizumab achieved a promising objective response ratio in renal cell carcinoma [81]. Simultaneous blockade of PD-L1 and VEGF can suppress formation of blood and lymphatic vessels in the tumours, and promote immune cell adhesion, trafficking and activation [82]. At the same time, the study also needs further protein/mRNA expression analysis to corroborate the results of immunohistochemistry. Furthermore, other possible drug combinations, such as anti-PD-L1 and anti-VEGF should also be tested in NSCLC. Therefore, clinical studies with larger cohorts are needed to fully investigate the therapeutic efficacy of BEV, APA and CDDP in NSCLC patients.
In summary, the combination of BEV, APA and CDDP prolonged survival of LLC tumour-bearing mice by reducing MPE and glucose metabolism. A better understanding of this combination will define new approaches to enhance drug efficacy in the treatment of NSCLC patients with MPE by possible moderation of VEGF/MAPK/ERK pathways.

**Acknowledgements**

The authors thank people who provided technical assistant in Oncology Department, The Affiliated Hospital of Southwest Medical University. The authors gratefully acknowledge research drugs provided by Hengrui Medicine. (Hengrui Co. Ltd., Lianyungang, Jiangsu, China). We also gratefully acknowledge all authors and co-workers for their contributions.
Ethics approval and consent to participate

All animal procedures must be performed in accordance with an approved protocol by an IACUC and National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 2017, revised 2019). Animal experiments were reviewed and approved by the Institutional Animal Care and Treatment Committee of Southwest Medical University, Sichuan, China. (No. SWMU20210391).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This work was supported by the Southwest Medical University and the Research Foundation of the Science and Technology Department of Sichuan Province [No. 2017-TD-2] and was funded by Q.L.W.

Data availability statement

All the datasets generated and analysed during the present study are available from the corresponding author on reasonable request.

References

[1] Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted Life-Years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1357–1768.

[2] Wong MCS, Lao XQ, Ho KF, et al. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300.

[3] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

[4] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.

[5] Froudarakis ME. Pleural effusion in lung cancer: more questions than answers. Respiration. 2012;83(5):367–376.

[6] Economidou F, Margantopoulos G, Antoniou KM, et al. The angiogenic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. Exp Ther Med. 2010;1(1):3–7.

[7] Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999; 5(11):3364–3368.

[8] Wang M, Zeng Q, Li Y, et al. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. J Drug Target. 2020;28(9):961–969.

[9] Qin W, Liu B, Yi M, et al. Antifibrotic agent pirfenidone protects against development of Radiation-Induced pulmonary fibrosis in a murine model. Radiat Res. 2018;190(4):396–403.

[10] E R, C A, J A, et al. Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung. 2005;183(3):185–195.

[11] M B, A M, T P. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15(3):207–216.

[12] Roviello G, Ravelli A, Polom K, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372(2):187–191.

[13] Tao H, Meng Q, Li M, et al. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. Thorac Cancer. 2018;9(2):298–304.

[14] Sabang RL, Ganghiraj D, Fanucchi M, et al. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018;12(2):87–94.

[15] Scott Lj. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–758.

[16] King M, Sensakovic WF, Maxim P, et al. Line-Enhanced deformable registration of pulmonary computed tomography images before and after radiation therapy with Radiation-Induced fibrosis. Technol Cancer Res Treat. 2018;17:153303461774941. 1533034617749419.

[17] Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454.

[18] Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–3225.

[19] Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2018;37(1):298–304.

[20] Li N, Wang Z, Yuan G, et al. An oral small molecule VEGF/R2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study. J Oncol. 2020;2020:3852373.

[21] Shao F, Zhang H, Yang X, et al. Adverse events and management of apatinib in patients with advanced or metastatic cancers: a review. Neoplasma. 2020;67(4):715–723.

[22] Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–4147.

[23] Fathi Maroufi N, Rashidi MR, Vaheidian V, et al. Therapeutic potentials of apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sci. 2020;241:117106.
[24] Tian S, Quan H, Xie C, et al. NY968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380.

[25] Nakamura K, Taguchi E, Miura T, et al. KRKN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antimetastatic activities and affects functional vascular properties. Cancer Res. 2006;66(18):9134–9142.

[26] Hicklin DJ, Ellis E. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.

[27] Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and Pro-Angiogenic therapies. Genes & Cancer. 2011;2(12):1097–1105.

[28] Verheul HM, Hoekman K, Jornal AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(51):45–50.

[29] Verheul HM, Hoekman K, Jornal AS, et al. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(51):45–50.

[30] Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFIRI) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol. 2007;25(12):1539–1544.

[31] Bagley SJ, Talento S, Mitra N, et al. Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous Non-Small cell lung cancer. J Nati Compr Canc Netw. 2019;17(5):469–477.

[32] Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a Meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(33):e11936.

[33] Bai ZG, Zhang ZT. A systematic review and Meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. OTT. 2018;11:7087.

[34] Xu MD, Liu L, Wu MY, et al. The combination of cantharidin and antiangiogenic therapies presents additive antitumor effects against pancreatic cancer. Oncogenesis. 2018;7(11):94.

[35] N D, X L, F L, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332–2340.

[36] J L, L P, G Z, et al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res. 2016;36(3):1313–1318.

[37] Acencio M, Puka J, Alvarenga VA, et al. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8(62):105093–105102.

[38] Liu W, Xu J, Wang M, et al. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol. 2011;39(5):1213–1220.

[39] Socinski MA, Evans T, Gettigser S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(S Suppl):e341S–e368S.

[40] Alan S, Robert G, al P. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.

[41] Liu ZJ, Zhou YJ, Ding RL, et al. In vitro and in vivo antipanib inhibits vasculogenic mimicry in melanoma MUM-2B cells. PLoS One. 2018;13(7):e0200845.

[42] Tissot C, Gay P, Brun C, et al. Novel insights into the systemic treatment of lung cancer malignant pleural effusion. Clin Respir J. 2019;13(3):131–138.

[43] Acencio MM, Puka J, Marchi E, et al. A modified experimental model of malignant pleural disease induced by lung lewis carcinoma (LLC) cells. J Transl Med. 2015;13:302.

[44] Ma X, Sun Y, Wang S, et al. Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein. Trans Lung Cancer Res. 2012;1(3):170–178.

[45] Xie SL, Yang MH, Chen K, et al. Efficacy of arsenic trioxide in the treatment of malignant pleural effusion caused by pleural metastasis of lung cancer. Cell Biochem Biophys. 2015;71(3):1325–1333.

[46] Nie K, Zhang Z, You Y, et al. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac Cancer. 2020;11(1):8–14.

[47] Lee KH, Ko BH, Paik JY, et al. Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med. 2005;46(9):1531–1536.

[48] Xie F, Ding RL, He WF, et al. In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410–1418.

[49] Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.

[50] van der Leest C, Smit EF, Baas J, et al. SUVmax during Eastern cooperative oncology group study E3200. J Clin Oncol. 2007;25(12):1539–1544.

[51] Braicu C, Buse M, Busuioc C, et al. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618.[

[52] Yano S, Shinohara H, Herbst RS, et al. Production of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410–1418.

[53] Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):380–387.
[54] Mallow C, Hayes M, Semaan R, et al. Minimally invasive palliative interventions in advanced lung cancer. Expert Rev Respir Med. 2018;12(7):605–614.

[55] Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8(4):294–301.

[56] Fafliora E, Hatzoglou C, Gourgoulianis KI, et al. Systematic review and Meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiol Rep. 2016;4(24):e12978.

[57] Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signaling. Nat Rev Mol Cell Biol. 2016;17(10):611–625.

[58] Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor, the. Journal of Biological Chemistry. 1994;269(43):26988–26995.

[59] Mori R, Fujimoto D, Ito M, et al. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 2017;8(29):48521–48524.

[60] Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6(3):957–965.

[61] Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer. 2011;104(8):1270–1277.

[62] Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC; focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8(1):15–27.

[63] Qiu H, Li J, Liu Q, et al. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with paclitaxel. Cell Cycle. 2018;17(10):1235–1244.

[64] Inoue S, Hartman A, Branch CD, et al. Mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007;15(2):287–294.

[65] Bao X, Wang M-W, Luo J-M, et al. Optimization of early response monitoring and prediction of cancer angiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters. Theranostics. 2016;6(12):2084–2098.

[66] Goggi JL, Bejot R, Moonshi SS, et al. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med. 2013;54(9):1630–1636.

[67] AD V. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. The oncologist null(undetermined) 2008. 8–13.

[68] Sun Y, Yu H, Ma J, et al. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8): e0161764.

[69] Nakajima R, Abe K, Sakai S. Diagnostic ability of FDG-PET/CT in the detection of malignant pleural effusion. Medicine (Baltimore. 2015;94(29):e1010.)

[70] C G, L-F N, T M, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Molecular Cancer Therapeutics. 2014;13(1):165–178.

[71] Collet G, Lamerant-Fayel N, Tertil M, et al. Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther. 2014;13(1):165–178.

[72] Xu W, Puligandla M, Manola J, et al. Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma. Clin Cancer Res. 2019;25(20):6098–6106.

[73] Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.

[74] Henriet P, Emonard H. Matrix metalloproteinase-2: Not (just) a "hero" of the past. Biochimie. 2019;166: 223–232.

[75] Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 2012;114:237–267.

[76] Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:3–4.

[77] Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptor tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8(1):15–27.

[78] Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and Pro-Angiogenic therapies. Genes Cancer. 2011;2(12):1097–1105.

[79] Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis. 2017;20(2): 185–204.

[80] Zhang L, Chen Y, Li F, et al. Atezolizumab and bevacizumab attenuate cisplatin-resistant ovarian cancer cells progression synergistically via suppressing Epithelial-Mesenchymal transition. Front Immunol. 2019;10:867.

[81] Gao X, McDermott DF. Combinations of bevacizumab with immune checkpoint inhibitors in renal cell carcinoma. Cancer J. 2018;24(4):171–179.

[82] Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9(2):115.